Cyclist receives sanction

2 March 2020

The Australian Sports Anti-Doping Authority (ASADA) acknowledges the decision of the Cycling Australia (CA) to impose a two-year ban on athlete Luke Van Maanenberg for the presence and use of prohibited substances.

Mr Van Maanenberg returned an Adverse Analytical Finding (AAF) from an in-competition doping control test on 9 April 2019.

His sample was analysed at the Australian Sports Drug Testing Laboratory, part of the National Measurement Institute, which detected the presence of Prohibited Substances Higenamine and Oxilofrine (methylsynephrine).

It was determined that on and/or before 9 April 2019 the athlete used a Prohibited Substance, namely Higenamine.

CA imposed a two-year ban on Mr Van Maanenberg commencing on 13 December 2019.

Mr Van Maanenberg is ineligible to participate in any sports that have adopted a World Anti-Doping Code compliant anti-doping policy until 13 December 2021. He is also not permitted to compete in a non-signatory professional league, or event organised by a non-signatory International or National level event organisation.

Additional information on the prohibited substance

Higenamine is classified as an S3 Beta-2 Agonist (these types of substances allow lungs to take in more oxygen) and is prohibited in and out-of-competition. However, as a cardiotonic, higenamine can increase heart rate, putting an athlete at an increased risk of arrhythmias and even death.

Oxilofrine (methylsynephrine) is classified as a S6.b specified stimulant under the 2019 Prohibited List. Stimulants can enhance performance through reducing tiredness and increasing alertness, competitiveness and aggression. Health effects include anxiety, sleep disorders, cerebral haemorrhage and heart attacks and possible sudden death.

ASADA is committed to protecting the right of clean athletes to fair competition. If you are aware of any suspicious doping activity, you can report it anonymously via the ASADA website: www.asada.gov.au/report-doping or call us on 13 000 27232.

Tags: